PIMS-TS in Intensive Care: Retrospective Cohort Trial (PIMS-TS INT)

Brno University Hospital

Status: Completed

Conditions: Pims-Ts

Treatments: Other: PIMS-TS diagnostic a treatment

Study type: Observational

Funder types: Other

Identifiers

NCT05388396

PIMS-TS INT

Details and patient eligibility

About

Pediatric Multisystem Inflammatory Syndrome Temporally associated with SARS-CoV-2, (PMIS-TS) represents the new unit, partially imitating the previously described Kawasaki disease. Due to variable and frequently incomplete clinical presentation together with variable disease severity, the real incidence in pediatric population remains unclear. Currently, PIMS-TS is defined by persistent fever, elevation of inflammatory markers, organ dysfunction (cardiac, central nervous system, respiratory, coagulation, renal, gastrointestinal), skin lesions (exanthematous), and absence of other possible etiology.

Full description

During the world COVID-19 pandemic (2020-2022), pediatric patients with PIMS-TS represented a significant part of pediatric intensive care unit (PICU) load. The initial clinical presentation of patients with PIMS-TS could vary significantly, and also due to progressively evolving recommendations, the diagnostic a therapy could vary regionally and over the time too. The aim of this retrospective cohort trial was to describe the initial clinical presentation, diagnostics, therapy and clinical outcome of pediatric patients admitted during 2020-2022 to the one of the 3 university hospital PICUs.

Enrollment: 180 patients

Sex: All

Ages: Under 19 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• pediatric patients with PIMS-TS
• PICU admission

Exclusion criteria

• insufficient data
• patients not admitted to PICU

Trial design

180 participants in 1 patient group

PIMS-TS patients

Description:

Pediatric patients with PIMS-TS admitted to the PICU in selected time period

Treatment:

Other: PIMS-TS diagnostic a treatment